23 Results Sort By:
ONC201 for the Treatment of Vascular Aneurysms
Application A repurposed therapeutic for the preventative and treatment of aneurysms. Key Benefits A repurposed cancer drug that targets cells known to be damaged during the progression of an aneurysm. The drug has been tested within an animal model of aortic aneurysms, where it prevented the severe complications of the disease and protected the...
Published: 5/23/2023       Contributor(s): Alejandra Maria San Martin
Therapeutic to Treat Age-Dependent Idiopathic Pulmonary Fibrosis
Application Therapeutic for treating age-associated lung fibrosis. Key Benefits Tecfidera (dimethyl fumarate - DMF) is an FDA approved therapy to treat multiple sclerosis via oral administration. A novel formulation for inhaled delivery demonstrated efficacy for a new indication: Idiopathic Pulmonary Fibrosis (IPF), where it promotes the reversal...
Published: 5/8/2023       Contributor(s): Louise Hecker, Kosuke Kato, Priyadarshini Muralidharan, Heidi Mansour
Use of MAST1 Inhibitor in Treatment of Platinum-Based Chemotherapy
­ Application A combination therapy product for treatment of patients having cisplatin-resistant cancer. Key Benefits Identified the use of MAST1 inhibitors (such as lestaurtinib) to target cisplatin-resistant cancer. Lestaurtinib sensitized cells to cisplatin treatment the most using a concentration that attenuates cell viability by less...
Published: 5/23/2023       Contributor(s): Sumin Kang, Jing Chen, Lingtao Jin
IACS-0107059 for Sensitizing Resistant Multiple Myeloma (MM) for Venetoclax Therapy
­ Application Combinatorial drug therapy for resistant multiple myeloma. Key Benefits Clinically approved drugs to repurpose for multiple myeloma. Therapies for multiple myeloma that is resistant to other therapies. Market Summary Multiple myeloma (MM) is a plasma cell malignancy. Despite the use of next generation immunomodulatory drugs...
Published: 5/4/2023       Contributor(s): Malathy (mala) Shanmugam, Aditi Sharma
A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199)
Application A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients. Key Benefits Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients. A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients. Market...
Published: 5/8/2023       Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
Repurposed Treatment for Cocaine Use Disorder
Application Repurposed drug for transcriptomic-driven treatment of cocaine use disorder. Key Benefits FDA-approved drug. Outperformed current targets undergoing clinical trials for CUD at the mRNA level. Market Summary Cocaine abuse is associated with substantial morbidity and mortality, and there are no approved medications for the treatment...
Published: 5/23/2023       Contributor(s): Rohan Palmer, Spencer Huggett
Drug Combination to Treat Lung Cancer Metastasis
Application Combination product co-targeting PDH and GLUT1 to inhibit lung cancer metastasis. Key Benefits Combination of drugs exhibits greater synergism in cancer cell lines (H1299, 4T1, H1792). Has potential to prevent metastasis in a variety of cancers. Decreases both cell viability and invasive area. Repurposed drugs. Market Summary Metastatic...
Published: 4/5/2023       Contributor(s): Malathy (mala) Shanmugam, Adam Marcus
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages. Key Benefits Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi. Relatively low regulatory risk because many...
Published: 4/5/2023       Contributor(s): Young-Sup Yoon, Ji Woong (Jay) Han, Hyunsuk Shim
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries. Key Benefits Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries. Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 8/5/2022       Contributor(s): Ahsan Husain, Nawazish Naqvi
Combination Therapy to Treat Pediatric Brain Tumor
Application Combination therapy (inhibition of STAT3 and YB-1) to treat medulloblastoma. Key Benefits Drug combination targets cancer stem cells. Increased apoptosis of cancer cells compared to current chemotherapeutic agents. Market Summary Medulloblastoma (MB) is the most common cancerous brain tumor that affects children and survival rates...
Published: 5/4/2023       Contributor(s): Tobey John MacDonald, Anna Kenney, James Felker, Abhinav Dey
1 2 3